Company
Every published round Shire plc took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Shire plc has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Shire plc, as distinct from the investments it has made.
Companies Shire plc has backed that another company then bought. An exit for the holding, not a deal Shire plc did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of Shire plc is recorded as having been acquired. | ||||
Companies Shire plc acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Company | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Fibrotech Therapeutics | Acquisition | 2014 | US$75m (A$85.6m) | Startup Daily, anthillonline.com |
Stories naming Shire plc. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Uniseed adds Monash and a four-university NSW collaboration, lifting its third fund by $6.75 million to $56.75 million; the article recalls past portfolio sales to Novartis, Shire and Schneider Electric.
Venture fund Uniseed led a million-dollar slice of probiotic drinks maker PERKii's four-million-dollar round, its first deal from its new $50 million fund, to fund a national launch.
Also Startup Daily
GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.
Also GBS Ventures·novartis.com·clinicalleader.com·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia